Project Lead for ‘Aadhara’ (Breast cancer patient support group) was established in 2008.
Aadhara is a Breast Cancer support group that stays in touch with patients and their kin throughout their treatment period and beyond for clinical follow-up. Aadhara also provides psychosocial support for patients and caretakers helping them cope with their disease.
The lab she works with is a breast cancer research group located on a medical college campus and is focused on understanding disease patterns, molecular mechanisms, and social-cultural issues underlying breast cancer in Indian women for the last 12+ years. We have completed a prospective longitudinal observational study comprising of over 378 breast cancer patients who are recruited to our study at diagnosis and followed up for clinical outcomes. She has been the key person involved in clinical follow-up and have managed to build a close rapport with all our patients and their families. She has managed to maintain long-term contact with 98% of the recruited women and the median follow-up is over 74 months as of 31st May 2017. This unique situation has enabled clinicians and researchers to arrive at the actual clinical trajectories of this disease in India.
Currently, she is associated in a DBT/Wellcome Trust India Alliance project as a coordinator for recruiting breast cancer patient, sample coronation, and clinical follow-up.
Rajarajan S, Korlimarla A, Alexander A, Anupama CE, Ramesh R, Srinath BS, Sridhar TS, Prabhu JS. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes. Frontiers in endocrinology. 2021:716.
Prabhu JS, Patil S, Rajarajan S, Ce A, Nair M, Alexander A, Ramesh R, Bs S, Sridhar T. Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis. Annals of oncology: official journal of the European Society for Medical Oncology. 2021 May;32(Suppl 2).
Alexander A, Murthy RS. Living with cancer: Urgent need for emotional health support. Indian Journal of Cancer. 2020 Jul 1;57(3):360.
Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, PS H, Kaul R, Alexander A, Raghavan R, BS S, TS S. miR?18a activates Wnt pathway in ER?positive breast cancer and is associated with poor prognosis. Cancer medicine. 2020 Aug;9(15):5587-97.
Alexander A, Sreenath K, Murthy RS. Beyond numbers–recent understanding of emotional needs of persons diagnosed with cancer 2007–2018. Indian journal of palliative care. 2020 Jan;26(1):120.
Murthy RS, Alexander A. Progress in psycho-oncology with special reference to developing countries. Current opinion in psychiatry. 2019 Sep 1;32(5):442-50.
Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, CE Anupama, Alexander A, Kaluve RS, Manjunath S, Correa M, Srinath BS, Patil S, Kalamdani A, Prasad M, Sridhar TS. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol. 2017 Mar;39(3):1010428317695028.
Alexander A, Kaluve R, Prabhu JS, Korlimarla A, Srinath BS, Manjunath S, Patil S, Gopinath KS, Sridhar TS. The impact of breast cancer on the patient and the family in Indian perspective. Indian journal of palliative care. 2019 Jan;25(1):66.
Rajarajan S, Prabhu J, Korlimarla A, Nair M, Alexander A, Kaluve R, Ps H, Raja U, Ramesh R, Patil S, Bs S. MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers. Annals of Oncology. 2018 Nov 1;29:ix18-9.
Prabhu JS, Korlimarla A, Anupama CE, Alexander A, Raghavan R, Kaul R, Desai K, Rajarajan S, Manjunath S, Correa M, Raman R. Dissecting the biological heterogeneity within hormone receptor positive her2 negative breast cancer by gene expression markers identifies indolent tumors within late stage disease. Translational oncology. 2017 Aug 1;10(4):699-706.
Nair MG, Prabhu JS, Remacle J, Korlimarla A, Kaluve RS, Alexander A, Patil S, Srinivas ST. Examination of the role of integrin ?3 in chemoresistance by analysis of residual NACT tumor specimens and knock-in experiments. Annals of Oncology. 2017 May 1;28:i16.
Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, Ce A, Alexander A, Kaluve RS, Manjunath S, Correa M. HR+ HER2? breast cancers with growth factor receptor–mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumor Biology. 2017 Mar;39(3):1010428317695028.
Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G. High expression of integrin ?6 in association with the Rho–Rac pathway identifies a poor prognostic subgroup within HER 2 amplified breast cancers. Cancer medicine. 2016 Aug;5(8):2000-11.
Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, Dendukuri N, Manjunath S, Correa M, Raman N, Kalamdani A, Prasad M, Gopinath KS, Srinath BS, Sridhar TS. A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. J Cancer. 2014 Jan 23;5(2):156-65.
Ramu D, Ramesh RS, Manjunath S, Shivakumar, Goel V, Hemnath GN, Alexander A. Pattern of External Breast Prosthesis Use by Post Mastectomy Breast Cancer Patients in India: Descriptive Study from Tertiary Care Centre. Indian J Surg Oncol. 2015 Dec;6(4):374-7.
Breast cancer in premenopausal women-Evaluation of the role of circulating steroid hormones in resistance to therapy.
Clinical follow-up of patients; Psycho-oncology counselling; Career counselling for students; Life skills training program.